Ipca Laboratories Limited is an Indian multinational pharmaceutical company headquartered in Mumbai. The company manufactures and markets more than 350 finished-dosage formulations and around 80 active pharmaceutical ingredients (APIs), covering therapeutic areas that include pain management, rheumatology, antimalarials, cardiovascular medicine, dermatology and anti-diabetics, and has an emerging biosimilars business. Its products are sold in over 100 countries, and it is one of India's larger API exporters, supplying more than 70 countries.
Subscribe to see IPCA Laboratories Limited’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
A few of IPCA Laboratories Limited's closest competitors — see the full list of competitors and alternatives →
Aarti Drugs Ltd. is a leading manufacturer of Active Pharmaceutical Ingredients (APIs) and pharmaceutical formulations based in Mumbai, India.
Cipla Limited, along with its associated entities, operates as a global pharmaceutical enterprise, specializing in the creation and distribution of a wide array of medicinal products. Its extensive portfolio includes both active pharmaceutical ingredients (APIs) and a diverse range of finished formulations, addressing numerous therapeutic areas such as cardiovascular diseases, metabolic disorders, HIV, respiratory conditions, urology, oncology, pediatric health, infectious diseases, critical care, hepatitis, women's health, ophthalmology, and neuropsychiatry. The company maintains a strong focus on respiratory treatments, offering various inhalers, nasal sprays, injectables, and biosimilars. Cipla has also forged significant partnerships, including a licensing arrangement with Merck & Co., Inc. for the manufacturing and commercialization of the investigational oral antiviral drug Molnupiravir, and a separate license agreement with Eli Lilly and Company for baricitinib, indicated for COVID-19. Furthermore, it collaborates with Dr. Reddy's Laboratories Ltd, Sun Pharmaceutical Industries Limited, Emcure Pharmaceuticals Limited, and Torrent Pharmaceuticals Limited for Molnupiravir's clinical trials. Established in 1935, Cipla's corporate headquarters are located in Mumbai, India.
Intas Pharmaceuticals Ltd. is a multinational pharmaceutical formulation development, manufacturing, and marketing company operating globally.
Ajanta Pharma Limited is a specialty pharmaceutical company headquartered in Mumbai, India. It provides quality medicines across more than 30 countries and maintains a strong leadership position in the branded generic business.
Unichem Laboratories Limited is a prominent pharmaceutical manufacturing company headquartered in Mumbai, Maharashtra, India, with international subsidiaries and a global product footprint.
Established in Indore, India in 1967, Alpa Laboratories Limited focuses on the manufacturing, marketing, and distribution of finished pharmaceutical products, both domestically within India and for export. The company offers a wide array of human-grade medications, encompassing ethical, generic, and over-the-counter varieties, available in diverse forms such as injections, tablets, capsules, eye and ear drops, ointments, creams, and gels. Furthermore, it supplies veterinary pharmaceuticals, including boluses, injections, and intra-mammary infusions. Its extensive product range addresses numerous therapeutic categories, including anti-infectives (covering antibacterials, antibiotics, antifungals, antiprotozoals, and antivirals), pain relievers, anti-inflammatory drugs, cold and cough remedies, cardiovascular treatments, anti-diabetic agents, nutritional supplements, psychotropic medicines, and specialized preparations for skin, ear, and eye care. Alpa Laboratories distributes its goods through a robust network comprising distributors, retail pharmacies, and hospitals. The company also extends its reach internationally, exporting its products to various regions across South and Central America, Africa, Asia, and the CIS countries.
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Post the link and the card appears automatically — each network fetches the image itself.